<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Drug Interactions Associated With Increased Risk of Myopathy/Rhabdomyolysis (<linkhtml href="#i4i_section_id_0079af9f-280b-401c-904e-ae6ea13da4a9">2.6</linkhtml>, <linkhtml href="#i4i_section_id_91913810-fed7-42f0-b805-4b14ea212c77">5.1</linkhtml>, <linkhtml href="#i4i_interactions_id_c5213451-8d4d-4d23-856a-327eb657a42a">7</linkhtml>, <linkhtml href="#i4i_pharmacokinetics_id_e5f85a40-d4af-4d78-b0ea-ab8c5d877b64">12.3</linkhtml>)</caption>
<col width="72%"></col>
<col width="28%"></col>
<tbody>
<tr>
<td stylecode="Rrule Botrule Toprule " valign="top">
<paragraph>Interacting Agents</paragraph>
</td>
<td stylecode="Botrule Lrule Toprule " valign="top">
<paragraph>Prescribing Recommendations </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir)</paragraph>
</td>
<td stylecode="Lrule Botrule " valign="middle">
<paragraph>Avoid atorvastatin</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>HIV protease inhibitor (lopinavir plus ritonavir)</paragraph>
</td>
<td stylecode="Lrule Botrule " valign="middle">
<paragraph>Use with caution and lowest dose necessary</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir)</paragraph>
</td>
<td stylecode="Lrule Botrule " valign="middle">
<paragraph>Do not exceed 20 mg atorvastatin daily</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>HIV protease inhibitor (nelfinavir)</paragraph>
<paragraph>Hepatitis C protease inhibitor (boceprevir) </paragraph>
</td>
<td stylecode="Botrule " valign="middle">
<paragraph>Do not exceed 40 mg atorvastatin daily</paragraph>
</td>
</tr>
</tbody>
</table>